For severe chronic rhinosinusitis with nasal polyps, novel stapokibart reduced symptoms and polyp size atop treatment with a ...

With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the market will grow ...

Rothschild & Co Redburn initiated coverage of Regeneron (REGN) with a Buy rating and $890 price target Published first on TheFly – the ultimate ...